If so, you may be interested to know that a doctor in your area is
conducting a clinical study to assess the safety and effectiveness of
a medication in patients with plaque psoriasis. In this study,
patients will switch from Enbrel® to the study medication, which is
FDA-approved to treat chronic severe plaque psoriasis but has not
been studied in psoriasis patients who are switching treatments.

To qualify for participation in this research study, you must:

• Be between the ages of 18 and 75 years old
• Have been diagnosed with plaque psoriasis
• Have been treated with Enbrel® (etanercept) for at least the
past 4 months
• Currently have psoriatic lesions

If you qualify and choose to participate in this study, you will
receive an initial consultation, study-related examinations, and
study medication at no cost to you. Compensation for travel may also
be provided.

To learn more, please visit our website at:
www.PlaquePsoriasisStudy.com/index.asp?c=yg6